[Webinar] Cell and gene therapies in Europe: Industry’s next frontier
Cell and gene therapies (CGTs) offer potential curative and restorative treatments for previously untreatable diseases. This comes at an extremely high cost with some CGTs exceeding one million Euros.
The European market for cell and gene therapies (CGTs) is expected to grow rapidly over the next few years. Despite this, the high cost of CGTs can be a barrier to patient access.
Manufacturers of innovative therapies must therefore consider how to face this challenge in the future, and the potential use of country-specific payment and/or access schemes to increase payer’s willingness to pay.
In this webinar, we will explore a deep dive into country-specific payment schemes used for CGT access across four major European markets: Germany, France, Italy and the UK. This includes an overview of how each country’s regulatory framework affects pricing decisions as well as insights into how these countries are approaching reimbursement for cell therapies.
Agenda:
- An overview of the CGT regulatory landscape across Europe (Germany, France, Italy and the UK)
- Understanding the reimbursement and access of CGTs across scope countries
- Exploring the key drivers of CGT pricing
- How innovative payment schemes are used for CGTs
- How GPI horizon – value-based price forecasting supports manufacturers in developing a country specific payment scheme
Details of webinar event
Time: 11am (EST) | 4pm (BST)
Date: Thursday, 20 October 2022
Presenters:
Emma Beards
GPI Associate Consultant
Emma Beards has extensive experience working within the pharmaceutical sector, including over 3 years as a qualified community pharmacist. Emma holds a Master of Pharmacy (MPharm) Degree from the University of Nottingham.
Shahela Kodabuckus
GPI Consultant
Shahela Kodabuckus is an experienced academic and consultant within HEOR. She has supported clients with economic and budget impact models and worked on HTA submissions and SMC for assets indicated for neurology, oncology, and rare diseases. Shay holds an MSc in Health Economics and Econometrics from the University of Birmingham.
Rachel Jao, MPH
GPI Head of Commercial Strategy
Rachel Jao specializes in technology-driven solutions that drive efficiency and empower decision-making to the pharmaceutical industry. She leverages on her expertise in market access, HEOR and pricing, coupled with data and analytics to achieve commercial excellence.
Share the Article:
Sign up to our mailing list to be informed of the latest webinars
